Shots:

• The approval is based on the P-III (EMPEROR-Preserved) trial to evaluate Jardiance (10mg, qd) vs PBO in 5988 adults with chronic HFpEF with/out diabetes
• The results showed a 21% & 3.3% relative & absolute risk reduction for the composite 1EPs of CV death or hospitalization for HF. In key 2EPs analysis, 27% reduction in relative risk of first &  recurrent hospitalizations for HF, breakthrough benefits for a widely underserved group
• In both EMPEROR-Preserved & EMPEROR-Reduced, the benefit was consistent across LVEF subgroups. Jardiance is the 1st HF therapy to demonstrate a significant risk reduction in CV death & hospitalization for HF regardless of ejection fraction

 Ref: Boehringer Ingelheim | Image: Wikipedia